A protein subunit vaccine elicits a balanced immune response that protects against Pseudomonas pulmonary infection

[1]  L. Novak,et al.  Nontypeable Haemophilus influenzae Infection Impedes Pseudomonas aeruginosa Colonization and Persistence in Mouse Respiratory Tract , 2021, Infection and immunity.

[2]  C. Taylor,et al.  Regulation of the Hypoxia-Inducible Factor (HIF) by Pro-Inflammatory Cytokines , 2021, Cells.

[3]  W. Picking,et al.  Effect of Two Unique Nanoparticle Formulations on the Efficacy of a Broadly Protective Vaccine Against Pseudomonas Aeruginosa , 2021, Frontiers in Pharmacology.

[4]  J. Gu,et al.  Development of a Chimeric Vaccine Against Pseudomonas aeruginosa Based on the Th17-Stimulating Epitopes of PcrV and AmpC , 2021, Frontiers in Immunology.

[5]  Jianping Ye,et al.  Hypoxia-inducible factor (HIF): The link between obesity and COVID-19 , 2020, Obesity Medicine.

[6]  S. Birket,et al.  Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by Pseudomonas aeruginosa , 2020, Frontiers in Immunology.

[7]  Zhenyu Cheng,et al.  Mice Lacking γδ T Cells Exhibit Impaired Clearance of Pseudomonas aeruginosa Lung Infection and Excessive Production of Inflammatory Cytokines , 2020, Infection and Immunity.

[8]  L. Morici,et al.  Immunological considerations in the development of Pseudomonas aeruginosa vaccines , 2020, Human vaccines & immunotherapeutics.

[9]  T. Schoeb,et al.  Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during Polymicrobial Airway Infections , 2020, Infection and Immunity.

[10]  L. O. Ladeira,et al.  Balanced Th1/Th2 immune response induced by a MSP1a functional motif coupled to multiwalled carbon nanotubes as anti-anaplasmosis vaccine in murine model. , 2019, Nanomedicine : nanotechnology, biology, and medicine.

[11]  K. Ishii,et al.  Antigen-specific Mucosal Immunity Regulates Development of Intestinal Bacteria-mediated Diseases. , 2019, Gastroenterology.

[12]  A. Oliver,et al.  Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections , 2019, Clinical Microbiology Reviews.

[13]  G. Priebe,et al.  Progress Toward the Elusive Pseudomonas aeruginosa Vaccine. , 2018, Surgical infections.

[14]  D. Kohane,et al.  PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia. , 2018, Vaccine.

[15]  A. Coppola,et al.  Pro-inflammatory cytokines activate hypoxia-inducible factor 3α via epigenetic changes in mesenchymal stromal/stem cells , 2018, Scientific Reports.

[16]  Amjad Ali,et al.  Prediction of vaccine candidates against Pseudomonas aeruginosa: An integrated genomics and proteomics approach. , 2017, Genomics.

[17]  Kelsey A. Gregg,et al.  Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery , 2017, mBio.

[18]  Youssif M. Ali,et al.  Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa. , 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[19]  J. Vincent,et al.  A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients , 2017, Critical Care.

[20]  H. Bayes,et al.  Interleukin-17 Is Required for Control of Chronic Lung Infection Caused by Pseudomonas aeruginosa , 2016, Infection and Immunity.

[21]  G. Irajian,et al.  Immunogenicity and protective efficacy of Pseudomonas aeruginosa type a and b flagellin vaccines in a burned mouse model. , 2016, Molecular immunology.

[22]  G. Rossi,et al.  IL-17A impairs host tolerance during airway chronic infection by Pseudomonas aeruginosa , 2016, Scientific Reports.

[23]  K. Yanagihara,et al.  Pseudomonas aeruginosa Bacteremia among Immunocompetent and Immunocompromised Patients: Relation to Initial Antibiotic Therapy and Survival. , 2016, Japanese journal of infectious diseases.

[24]  Yuquan Wei,et al.  X-ray Irradiated Vaccine Confers protection against Pneumonia caused by Pseudomonas Aeruginosa , 2016, Scientific Reports.

[25]  P. Ramsland,et al.  Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. , 2015, Molecular immunology.

[26]  Vidyashankara G. Iyer,et al.  Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants , 2015, Human vaccines & immunotherapeutics.

[27]  Gillian Dekkers,et al.  IgG Subclasses and Allotypes: From Structure to Effector Functions , 2014, Front. Immunol..

[28]  J. Vincent,et al.  Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa* , 2014, Critical care medicine.

[29]  Chuan Wu,et al.  IL-21 induces IL-22 production in CD4+ T-cells , 2014, Nature Communications.

[30]  Ian Kimber,et al.  Immunogenicity of therapeutic proteins: Influence of aggregation , 2013, Journal of immunotoxicology.

[31]  J. Clements,et al.  Broadly Protective Shigella Vaccine Based on Type III Secretion Apparatus Proteins , 2011, Infection and Immunity.

[32]  J. Goldberg,et al.  Mucosal Vaccination with a Multivalent, Live-Attenuated Vaccine Induces Multifactorial Immunity against Pseudomonas aeruginosa Acute Lung Infection , 2010, Infection and Immunity.

[33]  A. Hauser.  The type III secretion system of Pseudomonas aeruginosa: infection by injection , 2009, Nature Reviews Microbiology.

[34]  G. Kaiko,et al.  Immunological decision‐making: how does the immune system decide to mount a helper T‐cell response? , 2008, Immunology.

[35]  D. Leclerc,et al.  Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. , 2007, Virology.

[36]  N. Ohmagari,et al.  Risk factors for infections with multidrug‐resistant Pseudomonas aeruginosa in patients with cancer , 2005, Cancer.

[37]  J. Goldberg,et al.  Protection against Fatal Pseudomonas aeruginosa Pneumonia in Mice after Nasal Immunization with a Live, Attenuated aroA Deletion Mutant , 2003, Infection and Immunity.

[38]  J. Wiener-Kronish,et al.  Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury , 1999, Nature Medicine.

[39]  A. Kharazmi,et al.  Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T‐helper cell response , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[40]  J. Goldberg,et al.  Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate) , 1995, Infection and immunity.

[41]  R. Helmke,et al.  Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro , 1988, Infection and immunity.

[42]  A. Vella,et al.  Understanding how lipopolysaccharide impacts CD4 T-cell immunity. , 2008, Critical reviews in immunology.